Experience Innovative Biotechnology Solutions with Diagnomics Lab

 At Diagnomics Lab, we are committed to advancing precision medicine through innovative liquid biopsy technologies. Liquid biopsy enables the analysis of genetic and epigenetic biomarkers from a simple blood sample, providing a non-invasive alternative to traditional tissue-based testing.

Our liquid biopsy platform supports a broad range of clinical and research applications, from prenatal screening to cancer detection and disease monitoring, helping physicians and patients make informed decisions with greater confidence.

Diagnomics offers advanced Non-Invasive Prenatal Testing (NIPT) services designed to assess fetal chromosomal abnormalities using cell-free fetal DNA (cffDNA) isolated from maternal blood.

• Early prenatal screening from maternal blood
• High sensitivity and specificity
• Reduced need for invasive procedures
• Improved pregnancy management and counseling

Our NIPT platform supports comprehensive prenatal screening while prioritizing patient safety and comfort.

Early detection remains one of the most effective strategies for improving cancer outcomes. Diagnomics is developing and validating liquid biopsy solutions that identify cancer-associated genetic and epigenetic biomarkers from circulating tumor DNA (ctDNA) and other blood-based markers.

• Multi-cancer early detection research
• Risk assessment and stratification
• Identification of cancer-associated genomic alterations
• Support for personalized screening programs

By detecting molecular signals before clinical symptoms emerge, liquid biopsy has the potential to significantly improve early intervention and patient outcomes.

Liquid biopsy provides a powerful tool for monitoring cancer progression and treatment response over time.

• Monitoring treatment effectiveness
• Detecting minimal residual disease (MRD)
• Tracking tumor evolution
• Identifying recurrence at earlier stages
• Supporting personalized therapeutic decisions

Because testing can be performed repeatedly through routine blood collection, physicians can gain real-time insights into disease status while minimizing patient burden.

Diagnomics integrates multiple molecular analysis technologies to support liquid biopsy applications, including:

• Cell-free DNA (cfDNA) analysis
• Circulating tumor DNA (ctDNA) profiling
• DNA methylation and epigenetic biomarker analysis
• Next-Generation Sequencing (NGS)
• Digital PCR (dPCR)
• AI-driven bioinformatics and data interpretation

Our multidisciplinary approach combines genomics, epigenomics, and artificial intelligence to deliver actionable insights for precision healthcare.

Measure Your Biological Age. Understand Your Aging Journey.

Chronological age tells you how long you have lived. Biological age reveals how well your body is aging.

EpiClock™ is Diagnomics' proprietary epigenetic aging analysis service designed to estimate an individual's biological age using DNA methylation biomarkers. By analyzing age-associated epigenetic markers, EpiClock provides a scientifically grounded assessment of biological aging and age acceleration.

Biological age can differ significantly from chronological age due to genetics, lifestyle, environmental exposures, nutrition, stress, and overall health status.

Understanding biological age provides valuable insights into healthy aging, wellness optimization, and personalized longevity strategies.

Epigenetics refers to chemical modifications that regulate gene activity without changing the DNA sequence itself.

One of the most well-established biomarkers of aging is DNA methylation. Specific DNA methylation patterns change predictably as people age, making it possible to estimate biological age with remarkable accuracy.

EpiClock utilizes carefully selected age-associated CpG methylation markers and advanced computational algorithms to calculate biological age and evaluate age acceleration.

EpiClock provides actionable insights that can help individuals and healthcare professionals:

• Evaluate healthy aging status
• Monitor the effectiveness of lifestyle interventions
• Assess the impact of nutrition, exercise, and wellness programs
• Support longevity and preventive health initiatives
• Track aging changes over time
• Promote personalized health optimization strategies

The EpiClock Service offers both Blod and Buccal Swap simple, non-invasive solution for biological aging assessment.

• Blood or Easy buccal (cheek) swab collection
• Convenient at-home or clinic-based collection
• Compatible with large-scale wellness and research programs

• MassARRAY® iPLEX DNA methylation analysis
• Proprietary EpiClock algorithm
• Optimized epigenetic biomarker panel
• High analytical reproducibility and robustness

• Biological Age
• Chronological Age Comparison
• Age Difference (ΔAge)
• Speed of Aging
• Aging Trend Visualization
• Personalized Interpretation

1. Longevity & Wellness Programs
2. Support personalized healthy aging strategies and monitor intervention outcomes.
3. Precision Health Clinics
4. Integrate biological age assessment into preventive and precision medicine services.
5. Corporate Wellness Programs
6. Provide objective aging biomarkers for employee health initiatives.
7. Clinical Research
8. Utilize biological age as a measurable endpoint for intervention studies and aging-related research.
9. Nutritional & Lifestyle Programs
10. Track the impact of dietary, fitness, and behavioral modifications on biological aging.
11. Research-Based Innovation

EpiClock is developed by Diagnomics' multidisciplinary team of scientists specializing in genomics, epigenetics, bioinformatics, and precision medicine. Our ongoing research focuses on advancing epigenetic biomarkers for healthy aging, longevity science, and personalized healthcare applications.

 Every individual responds differently to medications. Genetic variations can influence how drugs are absorbed, metabolized, transported, and utilized by the body. Pharmacogenomics (PGx) uses genetic information to help healthcare providers select the most appropriate medication and dosage for each individual.

At Diagnomics, we provide comprehensive Pharmacogenomics services designed to support personalized treatment decisions, improve therapeutic outcomes, and reduce the risk of adverse drug reactions.

Pharmacogenomics is the study of how genetic differences affect an individual's response to medications.

By analyzing key genes involved in drug metabolism and response, healthcare providers can better understand:

• Which medications may be most effective
• Which medications may require dose adjustments
• Potential risks for adverse drug reactions
• Individual differences in drug metabolism
• Personalized treatment strategies

Pharmacogenomics is becoming an essential component of precision medicine across multiple therapeutic areas.

Diagnomics provides comprehensive PGx reports that translate complex genetic information into clinically actionable insights.

• Medication efficacy predictions
• Drug sensitivity assessments
• Potential toxicity risks
• Recommended dosage considerations

• Poor Metabolizer (PM)
• Intermediate Metabolizer (IM)
• Normal Metabolizer (NM)
• Rapid Metabolizer (RM)
• Ultra-Rapid Metabolizer (UM)

• Evidence-based interpretation
• Gene-drug interaction analysis
• Personalized medication recommendations
• Easy-to-understand physician reports

Depending on the panel selected, Diagnomics PGx testing may include analysis of clinically relevant genes such as:

• CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP3A5, CYP1A2
• VKORC1, DPYD, TPMT, UGT1A1, SLCO1B1, COMT,MTHFR
• Additional clinically actionable biomarkers

Our reports are continuously updated based on the latest scientific evidence and clinical guidelines.

• Anticoagulants
• Antiplatelet therapy
• Statins

• Chemotherapy response
• Targeted therapy support
• Toxicity prediction

• Antidepressants
• Antipsychotics
• ADHD medications

• Opioids
• Analgesics
• Anti-inflammatory medications

• Epilepsy medications
• Neurodegenerative disease management

• Preventive medication management
• Personalized healthcare strategies